Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 7, 2020Heart

Lipoprotein(a), a moving target: from the primary to secondary prevention of atherothrombotic events

View Full Paper
Ask AI
Bookmark
Share

Why the study?

While the role of elevated Lp(a) levels in the risk for a first atherothrombotic event is established, findings regarding its impact on outcomes in patients with pre-existing CVD have been inconsistent.

Design

Editorial

Authors

JBJosip A. Borovac

Discussion

Loading...

Member takes

Overview

Highlights Lp(a) atherothrombotic mechanisms; leaves open whether targeting apo(a) improves outcomes.

Key Points

Key points are not available for this paper at this time.

Cite This Study

Josip A. Borovac (2020) studied this question.

synapsesocial.com/papers/6a8797b672575bdad0e9c978https://doi.org/10.1136/heartjnl-2020-316919
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1HEART UK consensus statement on Lipoprotein(a): A call to action2019 · 247 citations
  2. 2Association of Lipoprotein(a) With Risk of Recurrent Ischemic Events Following Acute Coronary Syndrome2017 · 97 citations
  3. 32018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines2019 · 6,261 citations
  4. 42019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk2019 · 4,884 citations
  5. 5Lipoprotein(a) Levels and Recurrent Vascular Events After First Ischemic Stroke2016 · 59 citations